期刊文献+

携带SET-CAN融合基因儿童前T淋巴母细胞淋巴瘤1例并文献复习 被引量:1

Pediatric T-lymphoblastic lymphoma with SET-CAN fusion gene: a case report and review of the literatures
下载PDF
导出
摘要 目的探讨携带SET-CAN融合基因的儿童前T淋巴母细胞淋巴瘤的临床特点及该基因在血液恶性肿瘤发病中的可能机制。方法分析1例携带SET-CAN融合基因的儿童前T淋巴母细胞淋巴瘤的临床特点、治疗和预后情况,并对相关文献进行复习。结果本例患儿起病急,病情进展快,很快发生骨髓转移,受累范围广泛。按BCH-2003-LBL方案化疗,2周后骨髓完全缓解,化疗后第33天瘤灶消失,SET-CAN融合基因转为阴性,目前已维持治疗1年半,以SET-CAN融合基因做为MRD监测标志持续阴性。结论携带SET-CAN融合基因的前T淋巴母细胞淋巴瘤对化疗敏感,该基因在化疗后缓解期持续阴性,可能是预后良好的指标,SET-CAN融合基因可能成为监测淋巴瘤微小残留病的新标志。 Objective To explore the clinical characteristics of pediatric T-lymphoblastic lymphoma(T-LBL) with SET-CAN fusion gene and expound the potential mechanism of SET-CAN in haematopoietic malignancy.Methods Clinical characteristics,treatment and outcome of a T-LBL case were analyzed.Literatures related to SET-CAN were reviewed.Results The onset of the disease was acute.It progressed very quickly and involved the bone marrow early.The involvement was extensive.The patient was treated with BCH-2003-LBL protocol and got complete bone marrow remission 2 weeks after chemotherapy.The tumor mass disappeared and SET-CAN gene turned negative at the day of 33.Now the patient was in maintenance therapy.SET-CAN gene monitored as MRD marker kept negative during 1 and a half years maintenance treatment.Conclusion T-LBL with SET-CAN fusion gene was sensitive to chemotherapy.SET-CAN gene kept negative in remission after chemotherapy.It implied that SET-CAN gene might be a favorable prognostic factor and a new MRD marker of Lymphoblastic lymphoma.
出处 《中国小儿血液与肿瘤杂志》 CAS 2011年第2期74-77,共4页 Journal of China Pediatric Blood and Cancer
基金 北京市卫生局首都医学发展基金(2007-1030) 北京市科技新星计划(2008B65)资助
关键词 儿童 前T淋巴母细胞淋巴瘤 SET-CAN融合基因 Children T-Lymphoblastic lymphoma SET-CAN
  • 相关文献

参考文献13

  • 1张蕊.儿童非霍奇金淋巴瘤的残留病监测[J].中国小儿血液与肿瘤杂志,2009,14(1):8-11. 被引量:2
  • 2Quentmeier H,Schneider B,Ro¨hrs S,et al.SET-NUP214 fusion inacute myeloid leukemia-and T-cell acute lymphoblastic leukemia-de-rived cell lines. J Hematol Oncol . 2009
  • 3Rosati R,La Starza R,Barba G,et al.Cryptic chromosome 9q34deletion generates TAF-Ialpha/CAN and TAF-Ibeta/CAN fusiontranscripts in acute myeloid leukemia. Haematologica . 2007
  • 4Van Vlierberghe P,van Grotel M,Tchinda J,et al.The recurrentSET-NUP214 fusion as a newHOXAactivation mechanism in pediatricT-cell acute lymphoblastic leukemia. Blood . 2008
  • 5von Lindern M,Poustka A,Lerach H,et al.The (6;9)chromosometranslocation,associated with a specific subtype of acute nonlymphocyticleukemia,leads to aberrant transcription of a target gene on 9q34. Molecular and Cellular Biology . 1990
  • 6Amira N,Cancel-Tassin G,Bernardini S,et al.Expression in bladdertransitional cell carcinoma by real-time quantitative reverse transcriptionpolymerase chain reaction array of 65 genes at the tumor suppressorlocus 9q34.1-2:identification of 5 candidates tumor suppressorgenes. International Journal of Cancer . 2004
  • 7Shimoyama T,Kato K,Miyaji-Yamaguchi M,et al.Synergisticaction of MLL,a TRX protein with template activating factor-I,ahistone chaperone. FEBS Letters . 2005
  • 8von-Lindern M,Breems D,van-Baal S,et al.Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9)acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia. Genes Chromosomes and Cancer . 1992
  • 9von-Lindern M,van-Baal S,Wiegant J,et al.Can,a putative on-cogene associated with myeloid leukemogenesis,may be activated by fusion of its3′half to different genes:characterization of the set gene. Molecular and Cellular Biology . 1992
  • 10Ichijo T,Chrousos GP,Kino T.Activated glucocorticoid receptorinteracts with the INHATcomponent Set/TAF-Ibeta and releases itfrom a glucocorticoid-responsive gene promoter,relieving repression:i mplications for the pathogenesis of glucocorticoid resistance in acuteundifferentiated le. Molecular and Cellular Endocrinology . 2008

二级参考文献26

  • 1.临床病历讨论.肝硬化伴双下肢运动障碍[N].中国医学论坛报,2003.10.30.
  • 2Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol, 2007;25:579-586.
  • 3Zijlstra JM, Lindauer-van der Weft G, Hoekstra OS, et al. 18F- Fluorine-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica, 2006 ;91:522-529..
  • 4Terasawa T, Nihashi T, Hotta T, et al. 18F-FDG PET for posttherapy assessment of Hodgkin' s disease and aggressive Non-Hodgkin' s lymphoma: a systematic review. J Nucl Med, 2008 Jan;49 (1): 13-21.
  • 5Busch K, Keller T, Fuchs U etd. Identification of two distinct MYC breakpoint clusters and their association with various IGH breakpoint regions in the t ( 8 ; 14 ) translocations in sporadic Burkitt-lymphoma. Leukemia, 2007,21 (8) : 1739-1751.
  • 6Staber PB, Vesely P, Haq N et al. The oncoprotein NPM-ALK of anaplastic large cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood, 2007, (Epub ahead of print).
  • 7Amin HM and Lai R. Pathobiology of ALK + anaplastic large-cell lymphoma. Blood, 2007, [ Epub ahead of print).
  • 8Dunleavy K, Davis RE, Landgren O et al. BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?. Blood, 2007,109 (2) :843-844.
  • 9Dunleavy K, Staudt LM and Wilson WH. The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma. Leuk Lymphoma, 2007,48(6) : 1061 - 1063.
  • 10Dolken G, Detection of minimal residual disease. Adv Cancer Res, 2001 ;82 : 133-85.

共引文献1

同被引文献4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部